Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
39.29 USD | +3.34% |
|
+0.46% | -17.96% |
14/06 | Wedbush Adjusts Ultragenyx Pharmaceutical's Price Target to $45 From $48, Keeps Neutral Rating | MT |
14/06 | Sector Update: Health Care Stocks Lean Lower Pre-Bell Friday | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.96% | 3.44B | |
+15.48% | 122B | |
+20.47% | 113B | |
+8.24% | 22.84B | |
-19.85% | 20.72B | |
-16.19% | 16.51B | |
-13.66% | 16.39B | |
-44.35% | 15.83B | |
+2.76% | 13.49B | |
+67.00% | 11.67B |
- Stock Market
- Equities
- RARE Stock
- News Ultragenyx Pharmaceutical Inc.
- Ultragenyx Plans to File Biologics License Application for UX111 Late This Year or Early 2025